13750-68-0

Usage

Uses

Used in Pharmaceutical Industry:
4-METHYL-2-THIAZOLECARBOXALDEHYDE 97 is used as a key intermediate in the synthesis of selective cyclooxygenase-2 (COX-2) inhibitors. These inhibitors are important in the development of anti-inflammatory and pain-relieving medications. The thiazole-containing compounds, including 4-METHYL-2-THIAZOLECARBOXALDEHYDE 97, have demonstrated excellent oral activity, making them valuable in the pharmaceutical sector.
Used in Chemical Synthesis:
In the field of chemical synthesis, 4-METHYL-2-THIAZOLECARBOXALDEHYDE 97 serves as a versatile building block for the creation of various thiazole-based compounds. These compounds can be utilized in a wide range of applications, such as agrochemicals, dyes, and materials science. The unique properties of the thiazole ring make it an attractive candidate for the development of new molecules with potential applications in these industries.
Used in Flavor and Fragrance Industry:
4-METHYL-2-THIAZOLECARBOXALDEHYDE 97 is also used in the flavor and fragrance industry due to its characteristic odor and taste. The compound can be used to create unique and complex aromas for various applications, such as perfumes, cosmetics, and the food industry. Its ability to impart distinct sensory properties makes it a valuable asset in the development of new and innovative products in this sector.

InChI:InChI=1/C5H5NOS/c1-4-3-8-5(2-7)6-4/h2-3H,1H3

Upstream product

• 24622-44-4 (E)-4-methyl-2-styrylthiazole 
• 693-95-8 4-Methylthiazole 
• 68-12-2 N,N-dimethyl-formamide 
• 4394-85-8 4-morpholinecarboxaldehyde 
• 45534-10-9 2-ethenyl-4-methyl-1,3-thiazole 
• 7210-73-3 4-Methylthiazol-2-carbonsaeure-ethylester 
• 100516-76-5 4-methyl-1,3-thiazole-2-carbohydrazide 
• 541-58-2 2,4-dimethylthiazole 
• 89602-38-0 4-methyl-thiazole-2-yllithium 
• 103989-44-2 N-benzenesulfonyl-N'-(4-methyl-thiazole-2-carbonyl)-hydrazine 

Downstream Products

• 14542-16-6 4-methyl-1,3-thiazole-2-carboxylic acid 
• 55152-99-3 6-(4-methyl-thiazol-2-yl)-dibenzo[d,f][1,3]diazepine-5,7-diol 
• 13750-70-4 N-(4-methyl-thiazol-2-yl-methylidene)-phenyl-amine 
• 143896-82-6 C₁₂H₁₃N₃O₂S₂ 
• 13750-63-5 (4-methylthiazol-2-yl)-methanol 
• 50398-72-6 2-(chloromethyl)-4-methylthiazole 
• 1061178-50-4 [(E)-1-(4-methylthiazol-2-yl)methylidene]-2,4,6-trimethylphenylamine 
• 644950-37-8 N-methyl-1-(4-methyl-1,3-thiazol-2-yl)methaneamine 
• 1175052-25-1 (S)-2-cyclohexyl-1-(4-methylthiazol-2-yl)-3-nitropropan-1-one 

Relevant academic research and scientific papers

Potassium channel modulators

Provided are compounds of the formula: and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels.

A Continuous-Flow Process for Palladium-Catalyzed Olefin Cleavage by using Oxygen within the Explosive Regime

A continuous-flow protocol for Pd-catalyzed olefin cleavage by using molecular oxygen as the sole oxidant to give carbonyl compounds was explored. The developed flow protocol allowed the use of a low catalyst loading (0.1 mol %), and decomposition of the active catalyst was prevented through stabilization by poly(ethylene glycol)-400 (PEG-400), which was present as a cosolvent. Radical scavengers inhibited the reaction, which indicated the involvement of a free-radical path in the reaction mechanism. The applicability of the continuous-flow protocol was demonstrated on several olefin substrates. The continuous-flow process enabled safe and scalable olefin cleavage.

SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

1-(DIHYDRONAPHTHALENYL)PYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS

Provided are 1-(dihydronaphthalenyl)pyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy for the treatment of obesity and diabetes.

TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS

The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthama, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases. (I)

HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES

The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.

COMPOUNDS CONTAINING FUSED RINGS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.

Thiazole-annelated imidazolium salts: A new architecture for N-heterocyclic carbenes

A short synthesis of thiazole-annelated imidazolium salts is presented. Deprotonation of these salts allowed the formation of new N-heterocyclic carbenes (NHCs) and the investigation of their respective electronic properties, which were determined by X-ray crystal structure analysis and IR spectroscopy of the corresponding iridium carbonyl complexes. Finally, the ability of these NHCs to form the corresponding palladium complexes was demonstrated. Georg Thieme Verlag Stuttgart.

BICYCLIC COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The present invention provides bicyclic beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer’s disease.